Scientists at Agios Pharmaceuticals have shown that a mutated metabolic enzyme common to many brain cancers acts like an oncogene, reversing the previously held belief that it was not involved in cancer-causing activity. They also linked the mutation, IDH1, to a potential predictive biomarker for glioma patients. Their work helps validate a drug discovery apporach based on the study of proliferating cancer cell metabolism.
Mark L. Ratner
Scientists at Agios Pharmaceuticals Inc. have shown that a mutated form of a metabolic enzyme common to many brain cancers acts like an oncogene and may be a potential...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
